This story has been updated to reflect that the BioLegend-VIB partnership will focus on deployment rather than development of a single-cell technology.

NEW YORK (GenomeWeb) – Antibody provider BioLegend announced today a partnership with the Belgian life science research institute VIB to deploy a single-cell multi-omics technology.

Under the partnership, the parties will test and implement BioLegend's TotalSeq antibodies as part of a workflow combing single-cell proteomics with single-cell transcriptomics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.